Dicerna Pharmaceuticals, Inc. (DRNA) Releases Quarterly Earnings Results, Misses Expectations By $0.22 EPS
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22), Bloomberg Earnings reports. The business had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative return on equity of 210.01% and a negative net margin of 5,895.26%. Dicerna Pharmaceuticals’s revenue was up 192.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.68) earnings per share.
Dicerna Pharmaceuticals (NASDAQ DRNA) traded up $2.14 during trading on Friday, reaching $7.78. The company’s stock had a trading volume of 957,031 shares, compared to its average volume of 220,188.
A hedge fund recently raised its stake in Dicerna Pharmaceuticals stock. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 6.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,219 shares of the biopharmaceutical company’s stock after acquiring an additional 2,094 shares during the quarter. Northern Trust Corp owned approximately 0.17% of Dicerna Pharmaceuticals worth $114,000 at the end of the most recent quarter. 55.94% of the stock is owned by institutional investors and hedge funds.
Several research firms recently issued reports on DRNA. HC Wainwright reissued a “buy” rating and issued a $10.00 target price (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday. ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. Chardan Capital reissued a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. Finally, Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $6.81.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.